Olema Pharmaceuticals (OLMA) investor relations material

Strategic focus and pipeline overview

• Focused on ER+, HER2- breast cancer, the most common malignancy in women, with two clinical phase assets: palazestrant and a KAT6 inhibitor.

• Palazestrant is in two phase III trials (OPERA-01 and OPERA-02), with the first readout expected in fall from OPERA-01.

• KAT6 inhibitor showed monotherapy activity in ER+, HER2- breast cancer and castration-resistant prostate cancer; combinations with fulvestrant and palazestrant are ongoing.

• Cash position at end of Q1 was $505 million, providing runway into the second half of 2028, covering ongoing trials and potential commercialization.

Clinical trial updates and timelines

• OPERA-01 top-line data expected in fall, with results for both mutant and wild-type populations to be announced.

• OPERA-02 is enrolling well, with design differences from other trials to better mimic current practice patterns.

• KAT6 combination data with fulvestrant may be available by year-end or early next year.

• Expansion into castration-resistant prostate cancer and potential consideration for other indications like ovarian and lung cancer based on preclinical signals.

KAT6 inhibitor program insights

• Monotherapy data showed antitumor activity and favorable tolerability, with lower rates of Grade 3 neutropenia compared to Pfizer's program.

• Collaboration with Bayer to combine KAT6 inhibitor with NUBEQA in prostate cancer.

• Ongoing evaluation of triplet combinations (KAT6, palazestrant, CDK4/6) depending on tolerability and efficacy data.